Clinical trial designs for the early clinical development of therapeutic cancer vaccines.
about
Lost in Translation: Obstacles to Translational MedicineA Phase I/II adaptive design to determine the optimal treatment regimen from a set of combination immunotherapies in high-risk melanomaImproving the decision to pursue a phase 3 clinical trial by adjusting for patient-specific factors in evaluating phase 2 treatment efficacy data.Immune-based therapeutics for pediatric cancer.Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cellsTelomerase as a universal tumor-associated antigen for cancer immunotherapy.Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses.Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trialImproved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patientsRandomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian CancerZD6474--clinical experience to date.Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma2015 Guidance on cancer immunotherapy development in early-phase clinical studies.Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomasStudy design in dementia drug trials.Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancerStrategies for clinical trials in type 1 diabetesImmune therapies.A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patientsRandomized phase II designs.AAPS/RAPS/CAPRA collaborative program: exploring the challenges of drug regulation in a global environment: clinical concerns.A comparison of phase II study strategies.Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design.Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trialConcordance measure and discriminatory accuracy in transformation cure models.A Bayesian pick-the-winner design in a randomized phase II clinical trial.The Chinese Herbal Mixture Tien-Hsien Liquid Augments the Anticancer Immunity in Tumor Cell-Vaccinated Mice.Immunotherapy is different: Implications for vaccine clinical trial design.
P2860
Q24807071-22E1F95A-7287-4827-B268-260681CEF9E4Q30300873-2908E52E-EC51-42C6-B48F-5418926BFABDQ31123601-43123ED9-F0D8-4FD1-855D-CBE729380BC6Q33604121-1B91901E-F3D1-4F93-ABFB-E48DDF73BDD6Q34415738-C6D7CC97-A564-4197-9122-BA83D7D848F7Q34535727-3142866F-9F79-44CE-B3AE-A0D0B566D682Q34791108-9ED8F49C-9640-4FDF-874D-5C3186A1F179Q34806694-C929592C-C08D-4F02-93E7-85E01583E3FCQ35021619-AAD72009-036F-41C7-BE65-7CE7890565B1Q35251489-6545E6C0-45F6-42C7-B951-35C679E9F3FFQ36146882-617C72B7-53F1-4F77-B50D-0837D51F8351Q36294815-5850A0EC-6961-44EB-A9A3-E5C15A835EE8Q36467378-C2BE836D-AEC1-4DCC-A53E-18D1247835B0Q36478070-8E83CE84-2D89-4FC5-9CA7-467CD3FF1ED8Q36806597-0B7D876F-2ECC-4685-AF64-A3BE32E5C0AAQ36880037-2D1FF451-C86A-42D7-B4B0-6C88DF2D70DEQ36995370-796D8B53-8F9B-46A2-BA28-3866669AD1CBQ36998232-8816F9DA-A7EE-4536-BF23-487C5540833CQ37002959-89231137-8BF0-4D98-9AAE-8773A64B3755Q37173942-3ADA73E2-2CD2-46A8-95D1-858FF74BE50FQ37361487-A84E24B3-8242-4D07-A1B1-7F2B6BF853C6Q37375886-0057FEF8-B21D-48FA-90C7-FE3B01760E75Q37615969-E5000884-0588-4638-AA5F-A73DA75192E3Q37684364-745FC8F6-CAEE-4954-BF92-03BB9741DBD0Q38798132-D5E25996-7460-44C9-88B2-E76F3E54A9B0Q47095307-F222AA95-8AEF-4EC9-A929-B0225051E629Q50192037-95445CFB-6D48-4BC5-B14B-AEB6AEB8C829Q50652363-ED140D85-F405-4CEA-AF6F-E44ABC88C02A
P2860
Clinical trial designs for the early clinical development of therapeutic cancer vaccines.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Clinical trial designs for the early clinical development of therapeutic cancer vaccines.
@ast
Clinical trial designs for the early clinical development of therapeutic cancer vaccines.
@en
Clinical trial designs for the early clinical development of therapeutic cancer vaccines.
@nl
type
label
Clinical trial designs for the early clinical development of therapeutic cancer vaccines.
@ast
Clinical trial designs for the early clinical development of therapeutic cancer vaccines.
@en
Clinical trial designs for the early clinical development of therapeutic cancer vaccines.
@nl
prefLabel
Clinical trial designs for the early clinical development of therapeutic cancer vaccines.
@ast
Clinical trial designs for the early clinical development of therapeutic cancer vaccines.
@en
Clinical trial designs for the early clinical development of therapeutic cancer vaccines.
@nl
P2093
P1476
Clinical trial designs for the early clinical development of therapeutic cancer vaccines.
@en
P2093
A Hildesheim
C L Mackall
J A Berzofsky
M Hamilton
S L Topalian
S M Steinberg
P304
P356
10.1200/JCO.2001.19.6.1848
P407
P577
2001-03-01T00:00:00Z